A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Sirolimus (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Nov 2016 Planned End Date changed from 1 Jul 2020 to 1 Oct 2020.
- 07 Nov 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.
- 07 Nov 2016 Status changed from not yet recruiting to recruiting.